Pancreatic safety of GLP-1-based therapeutic agents: further insights from rodent studies?

about

Are incretin mimetics and enhancers linked to pancreatitis and malignant transformations in pancreas?Studying pancreatic risks caused by incretin-based therapies: is it a game? It's not a game!Reanalysis of study of pancreatic effects of incretin therapy: methodological deficiencies.

P2860

Q38255715-6754E62D-72D3-4A30-8DB5-3489E3B82F87 Q38601929-B31CB4C2-A6FB-466C-AB69-D2CA2D127543 Q47096196-0D1A5280-A4E0-4F31-B59C-078EB393E82B

P2860

Pancreatic safety of GLP-1-based therapeutic agents: further insights from rodent studies?

Item

http://www.wikidata.org/entity/Q50862636

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Pancreatic safety of GLP-1-bas ...... insights from rodent studies?

@en

Pancreatic safety of GLP-1-bas ...... insights from rodent studies?

@nl

type

Item

label

Pancreatic safety of GLP-1-bas ...... insights from rodent studies?

@en

Pancreatic safety of GLP-1-bas ...... insights from rodent studies?

@nl

prefLabel

Pancreatic safety of GLP-1-bas ...... insights from rodent studies?

@en

Pancreatic safety of GLP-1-bas ...... insights from rodent studies?

@nl

P1476

Pancreatic safety of GLP-1-bas ...... insights from rodent studies?

@en

P2860

Clinical pathology of endocrine tumors of the pancreas. Analysis of autopsy cases

The Physiology of Glucagon-like Peptide 1

Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice

Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats

Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model.

Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis.

Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes

The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species.

Liver-specific disruption of the murine glucagon receptor produces α-cell hyperplasia: evidence for a circulating α-cell growth factor.

No evidence of drug-induced pancreatitis in rats treated with exenatide for 13 weeks.

P2888

s00125-013-2984-z

P304

1869-1872

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00125-013-2984-Z

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jens Juul Holst

P577

2013-07-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

244991700

http://www.w3.org/2001/XMLSchema#string

P698

23820635

http://www.w3.org/2001/XMLSchema#string

Pancreatic safety of GLP-1-based therapeutic agents: further insights from rodent studies?

about

P2860

P2860

Pancreatic safety of GLP-1-based therapeutic agents: further insights from rodent studies?

description

name

type

label

prefLabel

P1433

P1476

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P356

P1433

P1476

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P5875

P698